Back to search results

A Study of PF-07868489 for Pulmonary Arterial Hypertension

This study is looking at the long-term safety and effects of PF-07868489, a medicine for pulmonary arterial hypertension (PAH). PAH is a condition where there's high blood pressure in the arteries leading from your heart to your lungs, making your heart work harder. You can join this study if you are 18 or older and have already participated in a previous study involving PF-07868489, completing all required treatments and assessments. Researchers will measure side effects, changes in lab tests, and vital signs to understand how well PF-07868489 is tolerated. This study is currently unclear on its recruitment status and plans to enroll 36 participants.

Study design
This is an open-label study, meaning both you and your healthcare team will know you are receiving PF-07868489. It is an extension of a previous study with the same medicine.
What's involved
You will receive PF-07868489 as an injection under your skin every 4 weeks. You must be willing to attend all scheduled visits, follow the treatment plan, and complete all lab tests and study procedures.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored for up to 111 weeks after the start of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07073820

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatment
Pfizer
~42 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:PF-07868489

At a glance

Recruiting sites
0 of 27 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over Baseline up to week 111
+2 more outcomes measured

Conditions

Pulmonary Hypertension

Explore related trials

Pulmonary Arterial Hypertension

NCT07073820

Where you'd take part

This study runs at 27 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Gachon University Gil Medical Center

    Incheon, Incheon-gwangyeoksi [incheon], South Koreano site contact published

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, Chinano site contact published

  • Hammersmith Hospital

    London, Greater London, United Kingdomno site contact published

  • Heart and Vascular Center

    San Francisco, Californiano site contact published

  • Hospital Universitario 12 de Octubre

    Madrid, Spainno site contact published

  • HUB Hôpital Erasme

    Brussels, Belgiumno site contact published

  • Kobe University Hospital

    Kobe, Hyōgo, Japanno site contact published

  • Mount Sinai Hospital

    New York, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Baseline up to week 111
  • Number of Participants With Change From Baseline in Laboratory Tests ResultsBaseline up to week 111
  • Number of Participants With Vital Sign AbnormalitiesBaseline up to week 111